August 22, 2014 6:13 PM ET

Biotechnology

Company Overview of Tularik Inc.

Company Overview

As of August 13, 2004, Tularik Inc. was acquired by Amgen Inc. Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity. The T487 would be used for treating immune disorders. Tularik has research stage collaborations with Amgen, Inc., relating to oncology targets; the pharmaceutical division of Japan Tobacco, Inc., relating to metabolic diseases; Sankyo Co., Ltd....

1120 Veterans Boulevard

South San Francisco, CA 94080

United States

Founded in 1991

Phone:

650-825-7000

Fax:

650-825-7303

Key Executives for Tularik Inc.

Tularik Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Advanced Technologies and Regenerative Medicine, LLC United States
Provasis Therapeutics, Inc. United States
Pacific Biotech, Inc. United States
Senex Biotechnology, Inc. United States
Ichor Medical Systems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tularik Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.